Myocardial ischemia-reperfusion injury (MIRI) is a common pathological process, typically occurring in situations such as cardiac surgery with cardiopulmonary bypass, after interventional treatment for acute myocardial infarction, and during organ transplantation. With the continuous increase in the incidence of cardiovascular diseases, the prevention and treatment of MIRI has become a hot topic i
Conditions
Interventions
Case group (N group) and control group (C group):None
Propofol group and Sevoflurane group:None
Sponsors
The Second Affiliated Hospital of Xi 'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Case group: 1.Patients scheduled for elective cardiac valve surgery under cardiopulmonary bypass were selected, ASA grade: II-III, aged 18-70 years, 2.There were no significant abnormalities in liver and kidney functions; 3.The body mass index (BMI) was 18-26 kg/m^2; 4.The ASA classification was grade II-III, and the New York Heart Association (NYHA) cardiac function classification was grade II-III; 5.The estimated operation time was <= 6 hours; Control group: The surgical type was elective non-cardiac surgery, and there were no significant hemodynamic fluctuations during the operation.
Exclusion criteria
Exclusion criteria: 1.Those with severe arrhythmia or heart failure before the operation, those with an ejection fraction of less than 35% before the operation, those with a history of myocardial infarction or cardiac surgery within the past 3 months, those with poorly controlled hypertension (systolic blood pressure >= 180 mmHg or diastolic blood pressure >= 110 mmHg), those with severe anemia before the operation (hemoglobin < 70 g/L), those with coagulation dysfunction, those who are resistant or allergic to heparin, those with malignant tumors, those with severe liver, kidney or lung dysfunction, those with a history of mental disorders or immune system diseases, those with concurrent severe infectious diseases, and those undergoing other cardiac surgeries simultaneously; 2.Those who used glucocorticoids and immunosuppressants before the operation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cardiac troponin (cTnI/cTnT), creatine kinase (CK-MB), NT-proBNP, expression levels of candidate genes, lactate (Study 2);Variations in expression levels of candidate genes (Study 3); | — |
Secondary
| Measure | Time frame |
|---|---|
| Age, Gender, BMI (Study 2);Cardiac troponin (cTnI/cTnT), creatine kinase (CK-MB), NT-proBNP, etc.(Study 3); | — |
Countries
China
Contacts
Public ContactBai Jie
The Second Affiliated Hospital of Xi 'an Jiaotong University
Outcome results
None listed